Radiotherapeutic study shows low exposure to healthy organs
Radiopharmaceuticals company Oncoinvent has announced the publication of clinical dosimetry data for Radspherin in ovarian and colorectal cancer in the Journal of Nuclear Medicine.
The publication reports results from nine patients enrolled in the dosimetry cohorts of the Phase I Radspherin studies, which demonstrated a favourable safety profile and encouraging efficacy signals.
“In early-phase clinical studies, dosimetry is essential to understand how radiation exposure relates to potential toxicity and identify potential dose-limiting tissues,” said Caroline Stokke, senior author of the publication, Head of Nuclear Medicine Physics at Oslo University Hospital and Chair of the European Association of Nuclear Medicine Dosimetry Committee. “This work also reflects the methodological complexity of dosimetry for alpha therapies, where imaging cannot always be directly applied. To address these challenges, we were able to use a combination approach, also including blood sampling and biokinetic modelling, to estimate normal tissue radiation exposure and provide a basis for evaluating safety.”
The dosimetry study, conducted at The Norwegian Radium Hospital, part of Oslo University Hospital, evaluated how radiation from Radspherin is distributed to normal tissues following treatment. Results showed that absorbed radiation doses to normal organs were below levels commonly associated with risks for complications, including for organs typically regarded as activity-limiting such as the kidneys and red bone marrow.
Kari Myren, Chief Medical Officer at Oncoinvent, said: “Unintended radiation exposure to normal organs, especially for the kidneys and red bone marrow, frequently represents a limitation for obtaining therapeutic doses of radiopharmaceuticals. Our results indicate very low radiation exposure to healthy organs after treatment, which is consistent with the favourable safety profile observed in our clinical trials and supports the further development of Radspherin to provide hope for patients for whom very limited treatment options exist.”